CoChat
Sign Up
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease

Arora, Tania, Prashar, Vikash, Singh, Randeep, Barwal, Tushar Singh, Changotra, Harish, Sharma, Arti, Parkash, Jyoti·2022·Molecular Neurobiology
DOI 10.1007/s12035-022-02950-z
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is a progressive degeneration of neurons due to the accumulation of amyloid-β peptide (Aβ) and hyper-phosphorylation of tau protein in the neuronal milieu leading to increased oxidative stress and apoptosis. Numerous factors contribute towards the progression of AD, including miRNA, which are 22-24 nucleotides long sequence which acts as critical regulators of cellular processes by binding to 3' UTR of mRNA, regulating its expression post-transcriptionally. This review aims to determine the miRNA with the most significant dysregulation in the brain and cerebrospinal fluid (CSF) of human patients. A systemized inclusion/exclusion criterion has been utilized based on selected keywords followed by screening of those articles to conclude a list of 8 highly dysregulated miRNAs based on the fold change of AD vs control patients, which could be used in clinical testing as these miRNAs play central role in the pathophysiology of AD. Furthermore, a network study of highly dysregulated miRNA estimated the association of these miRNA in the mediation of Aβ generation and aggregation, inhibition of autophagy, reduction of Aβ clearance, microglial and astrocytic activation, neuro-inflammation, tau hyper-phosphorylation, and synaptic loss.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12035-022-02950-z

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 73

  1. Karlawish J, Jack CR Jr, Rocca WA, Snyder HM, Carrillo MC (2017) Alzheimer’s disease: The next frontier-Special Report 2017. Alzheimer’s Dement : J Alzheimer’s Assoc 13(4):374–380. https://doi.org/10.1016/j.jalz.2017.02.006 · DOI
  2. 2021 Alzheimer’s disease facts and figures (2021). Alzheimer’s Dement : J Alzheimer’s Assoc 17 (3):327–406 https://doi.org/10.1002/alz.12328 · DOI
  3. Cardozo PL, de Lima IBQ, Maciel EMA, Silva NC, Dobransky T, Ribeiro FM (2019) Synaptic elimination in neurological disorders. Curr Neuropharmacol 17(11):1071–1095. https://doi.org/10.2174/1570159X17666190603170511 · DOI
  4. Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O (2020) Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease. Brain : J Neurol 143(4):1233–1248. https://doi.org/10.1093/brain/awaa068 · DOI
  5. Cutsuridis V, Yoshida M (2017) Editorial: memory processes in medial temporal lobe: experimental, theoretical and computational approaches. Front Syst Neurosci 11:19. https://doi.org/10.3389/fnsys.2017.00019 · DOI
  6. Metaxas A, Kempf SJ (2016) Neurofibrillary tangles in Alzheimer’s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res 11(10):1579–1581. https://doi.org/10.4103/1673-5374.193234 · DOI
  7. Zhang H, Ma Q, Zhang YW, Xu H (2012) Proteolytic processing of Alzheimer’s beta-amyloid precursor protein. J Neurochem 120(Suppl 1):9–21. https://doi.org/10.1111/j.1471-4159.2011.07519.x · DOI
  8. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. https://doi.org/10.1016/S0197-4580(02)00065-9 · DOI · Paper page
  9. Kaur D, Behl T, Sehgal A, Singh S, Sharma N, Bungau S (2021) Multifaceted Alzheimer’s disease: building a roadmap for advancement of novel therapies. Neurochem Res 46(11):2832–2851. https://doi.org/10.1007/s11064-021-03415-w · DOI
  10. Arab L, Sabbagh MN (2010) Are certain lifestyle habits associated with lower Alzheimer’s disease risk? J Alzheimer’s Dis : JAD 20(3):785–794. https://doi.org/10.3233/JAD-2010-091573 · DOI
  11. Killin LO, Starr JM, Shiue IJ, Russ TC (2016) Environmental risk factors for dementia: a systematic review. BMC Geriatr 16(1):175. https://doi.org/10.1186/s12877-016-0342-y · DOI
  12. Wei W, Wang ZY, Ma LN, Zhang TT, Cao Y, Li H (2020) MicroRNAs in Alzheimer’s Disease: function and potential applications as diagnostic biomarkers. Front Mol Neurosci 13:160. https://doi.org/10.3389/fnmol.2020.00160 · DOI · Paper page
  13. Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J (2019) MicroRNAs in Alzheimer’s Disease: diagnostic markers or therapeutic agents? Front Pharmacol 10:665. https://doi.org/10.3389/fphar.2019.00665 · DOI
  14. Catalanotto C, Cogoni C, ZardSo G (2016) MicroRNA in Control of gene expression: an overview of nuclear functions. Int J Mol Sci 17 (10) https://doi.org/10.3390/ijms17101712 · DOI
  15. Rabbito A, Dulewicz M, Kulczynska-Przybik A, Mroczko B (2020) Biochemical markers in Alzheimer’s disease. Int J Mol Sci 21 (6) https://doi.org/10.3390/ijms21061989 · DOI
  16. Chang L, Zhou G, Soufan O, Xia J (2020) miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res 48(W1):W244–W251. https://doi.org/10.1093/nar/gkaa467 · DOI
  17. Zhang L, Liao Y, Tang L (2019) MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res : CR 38(1):53. https://doi.org/10.1186/s13046-019-1059-5 · DOI
  18. Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW (2016) Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res 1646:139–151. https://doi.org/10.1016/j.brainres.2016.05.026 · DOI · Paper page
  19. Mao S, Sun Q, Xiao H, Zhang C, Li L (2015) Secreted miR-34a in astrocytic shedding vesicles enhanced the vulnerability of dopaminergic neurons to neurotoxins by targeting Bcl-2. Protein Cell 6(7):529–540. https://doi.org/10.1007/s13238-015-0168-y · DOI · Paper page
  20. Sarkar S, Engler-Chiurazzi EB, Cavendish JZ, Povroznik JM, Russell AE, Quintana DD, Mathers PH, Simpkins JW (2019) Over-expression of miR-34a induces rapid cognitive impairment and Alzheimer’s disease-like pathology. Brain Res 1721:146327. https://doi.org/10.1016/j.brainres.2019.146327 · DOI · Paper page
  21. Zhao Y, Bhattacharjee S, Jones BM, Dua P, Alexandrov PN, Hill JM, Lukiw WJ (2013) Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. NeuroReport 24(6):318–323. https://doi.org/10.1097/WNR.0b013e32835fb6b0 · DOI
  22. Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD (2014) Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-beta. J Neurosci Res 92(11):1581–1590. https://doi.org/10.1002/jnr.23421 · DOI
  23. Wang J, Fivecoat H, Ho L, Pan Y, Ling E, Pasinetti GM (2010) The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer’s disease neuropathology. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1804(8):1690–1694. https://doi.org/10.1016/j.bbapap.2009.11.015 · DOI
  24. Wong SY, Tang BL (2016) SIRT1 as a therapeutic target for Alzheimer’s disease. Rev Neurosci 27(8):813–825. https://doi.org/10.1515/revneuro-2016-0023 · DOI
  25. Abozaid OAR, Sallam MW, El-Sonbaty S, Aziza S, Emad B, Ahmed ESA (2022) Resveratrol-Selenium Nanoparticles Alleviate Neuroinflammation and Neurotoxicity in a Rat Model of Alzheimer’s disease by regulating Sirt1/miRNA-134/GSK3β expression. https://doi.org/10.1007/s12011-021-03073-7 · DOI
  26. Perdoncin M, Konrad A, Wyner JR, Lohana S, Pillai SS, Pereira DG, Lakhani HV, Sodhi K (2021) A Review of miRNAs as biomarkers and effect of dietary modulation in obesity associated cognitive decline and neurodegenerative disorders. Front Mol Neurosci 14:756499–756499. https://doi.org/10.3389/fnmol.2021.756499 · DOI
  27. Sorensen SS, Nygaard AB, Nielsen MY, Jensen K, Christensen T (2014) miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl Stroke Res 5(6):711–718. https://doi.org/10.1007/s12975-014-0364-8 · DOI
  28. Majer A, Medina SJ, Niu Y, Abrenica B, Manguiat KJ, Frost KL, Philipson CS, Sorensen DL, Booth SA (2012) Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice. PLoS Pathog 8(11):e1003002. https://doi.org/10.1371/journal.ppat.1003002 · DOI
  29. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, Bartsch U, Weskamp G, Blobel CP, Glatzel M, De Strooper B, Saftig P (2010) The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci : J Soc Neurosci 30(14):4833–4844. https://doi.org/10.1523/JNEUROSCI.5221-09.2010 · DOI · Paper page
  30. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Investig 113(10):1456–1464. https://doi.org/10.1172/JCI20864 · DOI · Paper page
  31. Akhter R, Shao Y, Shaw M, Formica S, Khrestian M, Leverenz JB, Bekris LM (2018) Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer’s disease. Neurobiol Aging 63:110–119. https://doi.org/10.1016/j.neurobiolaging.2017.11.007 · DOI
  32. Yuan XZ, Sun S, Tan CC, Yu JT, Tan L (2017) The role of ADAM10 in Alzheimer’s disease. J Alzheimer’s Dis: JAD 58(2):303–322. https://doi.org/10.3233/jad-170061 · DOI
  33. Wang LL, Min L, Guo QD, Zhang JX, Jiang HL, Shao S, Xing JG, Yin LL, Liu JH, Liu R, Guo SL (2017) Profiling microRNA from brain by microarray in a transgenic mouse model of Alzheimer’s disease. Biomed Res Int 2017:8030369. https://doi.org/10.1155/2017/8030369 · DOI
  34. Fu H, Possenti A, Freer R, Nakano Y, Hernandez Villegas NC, Tang M, Cauhy PVM, Lassus BA, Chen S, Fowler SL, Figueroa HY, Huey ED, Johnson GVW, Vendruscolo M, Duff KE (2019) A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci 22(1):47–56. https://doi.org/10.1038/s41593-018-0298-7 · DOI · Paper page
  35. Mei Y, Yuan Z, Song B, Li D, Ma C, Hu C, Ching YP, Li M (2008) Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience 151(3):771–779. https://doi.org/10.1016/j.neuroscience.2007.10.057 · DOI
  36. Hojati Zohreh, Omidi Farzaneh, Dehbashi Moein, Mohammad Soltani Bahram (2021) The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer’s Disease. Iran Biomed J 25(1):62–67. https://doi.org/10.29252/ibj.25.1.62 · DOI
  37. Wang X, Tan L, Lu Y, Peng J, Zhu Y, Zhang Y, Sun Z (2015) MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett 589(6):726–729. https://doi.org/10.1016/j.febslet.2015.02.001 · DOI
  38. Miao J, Jing J, Shao Y, Sun H (2020) MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer’s disease cell model. BMC Neurosci 21(1):33. https://doi.org/10.1186/s12868-020-00579-z · DOI
  39. Greene AN, Parks LG, Solomon MB, Privette Vinnedge LM (2020) Loss of DEK expression induces Alzheimer’s disease phenotypes in differentiated SH-SY5Y Cells. Front Mol Neurosci 13:594319. https://doi.org/10.3389/fnmol.2020.594319 · DOI
  40. Boscher E, Husson T, Quenez O, Laquerriere A, Marguet F, Cassinari K, Wallon D, Martinaud O, Charbonnier C, Nicolas G, Deleuze JF, Boland A, Lathrop M, Frebourg T, Consortium F, Campion D, Hebert SS, Rovelet-Lecrux A (2019) Copy Number variants in miR-138 as a Potential risk factor for early-onset Alzheimer’s disease. J Alzheimer’s Dis: JAD 68 (3):1243-1255 https://doi.org/10.3233/JAD-180940 · DOI
  41. Meng F, Zhang Y, Li X, Wang J, Wang Z (2017) Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway. Oncol Rep 38(3):1655–1662. https://doi.org/10.3892/or.2017.5838 · DOI
  42. Yeh M, Wang Y-Y, Yoo JY, Oh C, Otani Y, Kang JM, Park ES, Kim E, Chung S, Jeon Y-J, Calin GA, Kaur B, Zhao Z, Lee TJ (2021) MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. Sci Rep 11(1):9219. https://doi.org/10.1038/s41598-021-88615-8 · DOI
  43. Zheng S, Wei S, Wang X, Xu Y, Xiao Y, Liu H, Jia J, Cheng J (2015) Sphingosine kinase 1 mediates neuroinflammation following cerebral ischemia. Exp Neurol 272:160–169. https://doi.org/10.1016/j.expneurol.2015.03.012 · DOI
  44. Wang C, Xu T, Lachance BB, Zhong X, Shen G, Xu T, Tang C, Jia X (2021) Critical roles of sphingosine kinase 1 in the regulation of neuroinflammation and neuronal injury after spinal cord injury. J Neuroinflammation 18(1):50. https://doi.org/10.1186/s12974-021-02092-4 · DOI
  45. Geng L, Zhang T, Liu W, Chen Y (2018) miR-494-3p modulates the progression of in vitro and in vivo Parkinson’s disease models by targeting SIRT3. Neurosci Lett 675:23–30. https://doi.org/10.1016/j.neulet.2018.03.037 · DOI
  46. Teixeira AL, Gomes M, Medeiros R (2012) EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front Genet 3:286. https://doi.org/10.3389/fgene.2012.00286 · DOI
  47. Guedes JR, Santana I, Cunha C, Duro D, Almeida MR, Cardoso AM, de Lima MC, Cardoso AL (2016) MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer’s disease. Alzheimer’s Dement 3:7–17. https://doi.org/10.1016/j.dadm.2015.11.004 · DOI
  48. Zhang H, Feng Z, Huang R, Xia Z, Xiang G, Zhang J (2014) MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol 45(5):2143–2152. https://doi.org/10.3892/ijo.2014.2596 · DOI
  49. Qian Y, Song J, Ouyang Y, Han Q, Chen W, Zhao X, Xie Y, Chen Y, Yuan W, Fan C (2017) Advances in roles of miR-132 in the nervous system. Front Pharmacol 8:770–770. https://doi.org/10.3389/fphar.2017.00770 · DOI · Paper page
  50. Cătană C-S, Crişan C-A, Opre D, Berindan-Neagoe I (2020) Diagnostic and prognostic value of microRNAs for Alzheimer’s disease: a comprehensive meta-analysis. Med Pharm Rep 93(1):53–61. https://doi.org/10.15386/mpr-1393 · DOI
  51. Pichler S, Gu W, Hartl D, Gasparoni G, Leidinger P, Keller A, Meese E, Mayhaus M, Hampel H, Riemenschneider M (2017) The miRNome of Alzheimer’s disease: consistent downregulation of the miR-132/212 cluster. Neurobiol Aging 50(167):e161-167e110. https://doi.org/10.1016/j.neurobiolaging.2016.09.019 · DOI · Paper page
  52. Catapano F, Zaharieva I, Scoto M, Marrosu E, Morgan J, Muntoni F, Zhou H (2016) Altered Levels of MicroRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy. Mol Therapy Nucleic Acids 5(7):e331. https://doi.org/10.1038/mtna.2016.47 · DOI
  53. Freischmidt A, Muller K, Ludolph AC, Weishaupt JH (2013) Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 1:42. https://doi.org/10.1186/2051-5960-1-42 · DOI
  54. Hebert SS, Wang WX, Zhu Q, Nelson PT (2013) A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer’s disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimer’s Dis: JAD 35(2):335–348. https://doi.org/10.3233/JAD-122350 · DOI · Paper page
  55. Johnson R, Buckley NJ (2009) Gene dysregulation in Huntington’s disease: REST, microRNAs and beyond. NeuroMol Med 11(3):183–199. https://doi.org/10.1007/s12017-009-8063-4 · DOI
  56. Gillardon F, Mack M, Rist W, Schnack C, Lenter M, Hildebrandt T, Hengerer B (2008) MicroRNA and proteome expression profiling in early-symptomatic alpha-synuclein(A30P)-transgenic mice. Proteomics Clin Appl 2(5):697–705. https://doi.org/10.1002/prca.200780025 · DOI
  57. Salta E, Sierksma A, Vanden Eynden E, De Strooper B (2016) miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Mol Med 8(9):1005–1018. https://doi.org/10.15252/emmm.201606520 · DOI · Paper page
  58. Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, Rothman R, Sierksma AS, Thathiah A, Greenberg D, Papadopoulou AS, Achsel T, Ayoubi T, Soreq H, Verhaagen J, Swaab DF, Aerts S, De Strooper B (2013) Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med 5(10):1613–1634. https://doi.org/10.1002/emmm.201201974 · DOI · Paper page
  59. Salta E, De Strooper B (2017) microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer’s disease. FASEB Journal: Offi Pub Fed American Soc Exp Biol 31(2):424–433. https://doi.org/10.1096/fj.201601308 · DOI · Paper page
  60. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S (2005) A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 102(45):16426–16431. https://doi.org/10.1073/pnas.0508448102 · DOI · Paper page
  61. Zhang M, Bian Z (2021) Alzheimer’s Disease and microRNA-132: A widespread pathological factor and potential therapeutic target. Frontiers in Neuroscience 15 https://doi.org/10.3389/fnins.2021.687973 · DOI
  62. Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, Boxer A, Rosen H, Miller BL, Laforce R Jr, Galimberti D, Masellis M, Borroni B, Zhang Z, Zinman L, Rohrer JD, Tartaglia MC, Robertson J, Genetic FTDI (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89(8):851–858. https://doi.org/10.1136/jnnp-2017-317492 · DOI · Paper page
  63. Gamez-Valero A, Campdelacreu J, Vilas D, Ispierto L, Rene R, Alvarez R, Armengol MP, Borras FE, Beyer K (2019) Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer’s disease and dementia with Lewy bodies. Transl Neurodegener 8:31. https://doi.org/10.1186/s40035-019-0169-5 · DOI · Paper page
  64. Koopaei NN, Chowdhury EA, Jiang J, Noorani B, da Silva L, Bulut G, Hakimjavadi H, Chamala S, Bickel U, Schmittgen TD (2021) Enrichment of the erythrocyte miR-451a in brain extracellular vesicles following impairment of the blood-brain barrier. Neurosci Lett 751:135829. https://doi.org/10.1016/j.neulet.2021.135829 · DOI · Paper page
  65. Zhang K, Bao R, Huang F, Yang K, Ding Y, Lauterboeck L, Yoshida M, Long Q, Yang Q (2021) ATP synthase inhibitory factor subunit 1 regulates islet beta-cell function via repression of mitochondrial homeostasis. Lab Investig: J Tech Methods Pathol https://doi.org/10.1038/s41374-021-00670-x · DOI
  66. Mohammed CP, Rhee H, Phee BK, Kim K, Kim HJ, Lee H, Park JH, Jung JH, Kim JY, Kim HC, Park SK, Nam HG, Kim K (2016) miR-204 downregulates EphB2 in aging mouse hippocampal neurons. Aging Cell 15(2):380–388. https://doi.org/10.1111/acel.12444 · DOI
  67. Zhang L, Fang Y, Zhao X, Zheng Y, Ma Y, Li S, Huang Z, Li L (2021) miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway. Mol Therapy Nucleic Acids 24:822–831. https://doi.org/10.1016/j.omtn.2021.02.010 · DOI
  68. Zhu X, Yu L, Tao W, Jin J, Xu Y (2019) O3–01–05: MIR-204 attenuates memory deficits in a mouse model of Alzheimer’s disease. Alzheimer’s Dement 15(7s_Part_17):P876–P877. https://doi.org/10.1016/j.jalz.2019.06.4628 · DOI
  69. Moncini S, Salvi A, Zuccotti P, Viero G, Quattrone A, Barlati S, De Petro G, Venturin M, Riva P (2011) The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS ONE 6(5):e20038. https://doi.org/10.1371/journal.pone.0020038 · DOI · Paper page
  70. Schmidt MF (2014) Drug target miRNAs: chances and challenges. Trends Biotechnol 32(11):578–585. https://doi.org/10.1016/j.tibtech.2014.09.002 · DOI
  71. Walgrave H, Zhou L, De Strooper B, Salta E (2021) The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives. Mol Neurodegener 16(1):76. https://doi.org/10.1186/s13024-021-00496-7 · DOI
  72. Chakraborty C, Doss CG, Bandyopadhyay S, Agoramoorthy G (2014) Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley interdisciplinary reviews RNA 5(5):697–712. https://doi.org/10.1002/wrna.1240 · DOI
  73. De Sousa RAL, Improta-Caria AC (2022) Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training. Metab Brain Dis 37(3):559–580. https://doi.org/10.1007/s11011-022-00903-y · DOI

Cited by

Sorted by citations

See all 37

Metadata

Authors
Arora, T., Prashar, V., Singh, R., Barwal, T. S., Changotra, H., Sharma, A., & Parkash, J.
ORCID
Parkash, Jyoti
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2022-07-22
Volume
59
Issue
10
Pages
6107-6124
ISSN
  • 0893-7648
  • 1559-1182
DOI
10.1007/s12035-022-02950-z
Cited by
37
References
9
Language
en
Licence
Funders
  • University Grants Commission (F.30-312/2016 (BSR))
  • Science and Engineering Research Board (CRG/2015/000240, CRG/2020/003257)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review